KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Prepaid Assets (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Prepaid Assets for 9 consecutive years, with $17.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 24.94% year-over-year to $17.2 million, compared with a TTM value of $17.2 million through Dec 2025, up 24.94%, and an annual FY2025 reading of $17.2 million, up 24.94% over the prior year.
  • Prepaid Assets was $17.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from $16.5 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $20.0 million in Q3 2023 and bottomed at $12.5 million in Q2 2025.
  • Average Prepaid Assets over 3 years is $16.2 million, with a median of $16.4 million recorded in 2024.
  • The sharpest move saw Prepaid Assets fell 29.63% in 2024, then grew 24.94% in 2025.
  • Year by year, Prepaid Assets stood at $19.5 million in 2023, then dropped by 29.63% to $13.8 million in 2024, then increased by 24.94% to $17.2 million in 2025.
  • Business Quant data shows Prepaid Assets for BCRX at $17.2 million in Q4 2025, $16.5 million in Q3 2025, and $12.5 million in Q2 2025.